---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-163909"
form_type: "8-K"
ticker: "DMRA"
cik: "0001800315"
company_name: "Damora Therapeutics, Inc."
filed_at: "2026-04-20T23:59:59+00:00"
generated_at: "2026-05-15T05:21:23.146076+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Damora Therapeutics dismisses EY Denmark auditor, appoints EY US

## Summary
- Audit Committee dismissed EY Denmark on April 17, 2026; EY US appointed same day.
- No disagreements or reportable events occurred in FY 2024 or 2025 or the subsequent interim period.
- EY Denmark's 2024 report included a going-concern explanatory paragraph.
- Company provided EY Denmark with disclosures; EY Denmark's letter to SEC filed as Exhibit 16.1.

## SEC filing metadata
- accession: 0001193125-26-163909
- form_type: 8-K
- ticker: DMRA
- cik: 0001800315
- company_name: Damora Therapeutics, Inc.
- filed_at: 2026-04-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 4.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1800315/000119312526163909/0001193125-26-163909-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1800315/000119312526163909/dmra-20260417.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-163909
- JSON: https://secwatch.observer/filing/0001193125-26-163909.json
- Plain text: https://secwatch.observer/filing/0001193125-26-163909.txt

## Source-grounded claims
- claim_id: 4c265f0fd44a09d9a517d4574dc12eda9fba203c
  claim: Damora Therapeutics, Inc. dismissed EY Godkendt Revisionspartnerselskab as its auditor.
  evidence_excerpt: On April 17, 2026, the Audit Committee (the “Audit Committee”) of the Board of Directors (the “Board”) of Damora Therapeutics, Inc., a Delaware corporation (the “Company”), dismissed EY Godkendt Revisionspartnerselskab (“EY Denmark”) as the Company’s independent registered public accounting firm, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1800315/000119312526163909/0001193125-26-163909-index.htm
- claim_id: 8ff55ccb6845c5b166ffb7f2e5d60a8e543fb7b5
  claim: Damora Therapeutics, Inc. engaged Ernst & Young LLP as its auditor.
  evidence_excerpt: On April 17, 2026, the Audit Committee engaged Ernst & Young LLP (“EY US”) as the Company’s independent registered public accounting firm, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1800315/000119312526163909/0001193125-26-163909-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.